ArticleBMC cancer2025
Lung cancer and COVID-19 susceptibility and severity: a Mendelian randomization analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
It has been observed that lung cancer patients are more susceptible to COVID-19. Establishing the causal relationships between lung cancer and COVID-19 susceptibility and severity is challenging due to numerous confounding factors. Mendelian randomization (MR) is an effective method to investigate the causal association between exposure and outcome variables. However, different studies have yielded conflicting conclusions regarding the role of lung cancer in COVID-19 susceptibility and severity. Lung cancer subtypes exhibit heterogeneity in genetic susceptibility, which may influence the assessment of the true relationship between lung cancer and COVID-19 susceptibility and severity. In this study, we utilized the most recent COVID-19 association data from The COVID-19 Host Genetics Initiative with more than two million samples in total, in combination with genetic data of different lung cancer subtypes with more than eighty-five thousand samples, and conducted a two-sample Mendelian randomization study. We examined the associations between lung cancer and its four subtypes with COVID-19 susceptibility, hospitalization, and severity. Our data indicates that lung cancer, overall, does not have a causal association with COVID-19 susceptibility, hospitalization, or severity. However, lung cancer in ever smokers is nominally associated with COVID-19 hospitalization p-value 0.035, false discover rate (FDR) [Formula: see text] and increased severity [Formula: see text], [Formula: see text]. Additionally, small cell lung carcinoma is associated with increased COVID-19 severity [Formula: see text], [Formula: see text].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.